Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Gayong | - |
dc.contributor.author | Han, Su-Eun | - |
dc.contributor.author | Yu, Yong-Hee | - |
dc.contributor.author | Lee, Sangbin | - |
dc.contributor.author | Lee, Han Young | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.contributor.author | Kwon, Ick Chan | - |
dc.contributor.author | Park, Tae Gwan | - |
dc.contributor.author | Kim, Young Bong | - |
dc.contributor.author | Choi, Yong Seok | - |
dc.contributor.author | Kim, Chan-Wha | - |
dc.contributor.author | Oh, Yu-Kyoung | - |
dc.date.accessioned | 2021-09-07T07:25:29Z | - |
dc.date.available | 2021-09-07T07:25:29Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-10-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111384 | - |
dc.description.abstract | Oligolysine-based cationic lipid derivatives were synthesized for delivery of siRNA, and formulated into cationic liposomes. Among various oligolysine-based lipid derivatives differing in lysine residue number and lipid moiety, trilysinoyl oleylamide (TLO)-based liposomes (TLOL) showed the highest delivery efficiency combined with minimal cytotoxicity. Delivery of siRNA using TLOL silenced target genes both in vitro and in vivo. In green fluorescent protein (GFP)-expressing tumor tissue, a significant reduction of fluorescence was observed after intratumoral administration of siGFP using TLOL compared with control siGL2. Intravenous administration of siMcl1 employing pegylated TLOL (pTLOL) reduced the expression of human Mcl1 protein in KB-xenografted tumor tissue. Despite the reduction in target protein Mcl1 expression following such systemic delivery, tumor growth was only slightly reduced compared to a siGL2-treated control group. To potentiate the anticancer activity of siMcl1, the anticancer drug suberoylanilide hydroxamic acid (SAHA) was additionally encapsulated in pTLOL After intravenous administration of siMcl1 using SAHA-loaded pTLOL (pSTLOL), a significant reduction in tumor growth was observed compared to that seen in animals treated with free SAHA or siGL2 complexed with pSTLOL. The results indicate that pTLOL could be further developed as a systemic delivery system for synergistic anticancer siRNA and a drug. (C) 2010 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | DOWN-REGULATION | - |
dc.subject | LEUKEMIA-CELLS | - |
dc.subject | GENE DELIVERY | - |
dc.subject | CANCER-CELLS | - |
dc.subject | MCL-1 | - |
dc.subject | VORINOSTAT | - |
dc.subject | INHIBITOR | - |
dc.subject | APOPTOSIS | - |
dc.subject | COMBINATION | - |
dc.subject | RESISTANCE | - |
dc.title | Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Ick Chan | - |
dc.contributor.affiliatedAuthor | Choi, Yong Seok | - |
dc.contributor.affiliatedAuthor | Kim, Chan-Wha | - |
dc.identifier.doi | 10.1016/j.jconrel.2010.10.017 | - |
dc.identifier.scopusid | 2-s2.0-80052145802 | - |
dc.identifier.wosid | 000295998200011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.155, no.1, pp.60 - 66 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 155 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 60 | - |
dc.citation.endPage | 66 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | LEUKEMIA-CELLS | - |
dc.subject.keywordPlus | GENE DELIVERY | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | MCL-1 | - |
dc.subject.keywordPlus | VORINOSTAT | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordAuthor | Trilysinoyl oleylamide | - |
dc.subject.keywordAuthor | Cationic liposome | - |
dc.subject.keywordAuthor | Co-delivery | - |
dc.subject.keywordAuthor | siRNA | - |
dc.subject.keywordAuthor | Suberoylanilide hydroxamic acid | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.